BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonner MY, Karlsson I, Rodolfo M, Arnold RS, Vergani E, Arbiser JL. Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 2016;7:12857-68. [PMID: 26871475 DOI: 10.18632/oncotarget.7289] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Hossain M, Roth S, Dimmock JR, Das U. Cytotoxic derivatives of dichloroacetic acid and some metal complexes. Archiv der Pharmazie. [DOI: 10.1002/ardp.202200236] [Reference Citation Analysis]
2 Li Y, Liang C, Zhou X. The application prospects of honokiol in dermatology. Dermatol Ther 2022;:e15658. [PMID: 35726011 DOI: 10.1111/dth.15658] [Reference Citation Analysis]
3 Hossain M, Roayapalley PK, Sakagami H, Satoh K, Bandow K, Das U, Dimmock JR. Dichloroacetyl Amides of 3,5-Bis(benzylidene)-4-piperidones Displaying Greater Toxicity to Neoplasms than to Non-Malignant Cells. Medicines 2022;9:35. [DOI: 10.3390/medicines9060035] [Reference Citation Analysis]
4 Radi R, Huang C, Elsey J, Jung YH, Corces VG, Arbiser JL. Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo. Antioxidants 2022;11:798. [DOI: 10.3390/antiox11050798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dahmardeh Ghalehno A, Boustan A, Abdi H, Aganj Z, Mosaffa F, Jamialahmadi K. The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition. Nutr Cancer 2022;:1-27. [PMID: 34994266 DOI: 10.1080/01635581.2021.2022169] [Reference Citation Analysis]
6 Huang C, Radi RH, Arbiser JL. Mitochondrial Metabolism in Melanoma. Cells 2021;10:3197. [PMID: 34831420 DOI: 10.3390/cells10113197] [Reference Citation Analysis]
7 Leo A, Pranzini E, Pietrovito L, Pardella E, Parri M, Cirri P, Bruno G, Calvani M, Peppicelli S, Torre E, Sasaki M, Yang L, Zhu L, Chiarugi P, Raugei G, Arbiser JL, Taddei ML. Claisened Hexafluoro Inhibits Metastatic Spreading of Amoeboid Melanoma Cells. Cancers (Basel) 2021;13:3551. [PMID: 34298765 DOI: 10.3390/cancers13143551] [Reference Citation Analysis]
8 Anwar S, Shamsi A, Mohammad T, Islam A, Hassan MI. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochim Biophys Acta Rev Cancer 2021;1876:188568. [PMID: 34023419 DOI: 10.1016/j.bbcan.2021.188568] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
9 Li XQ, Ren J, Wang Y, Su JY, Zhu YM, Chen CG, Long WG, Jiang Q, Li J. Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction. Cell Oncol (Dordr) 2021;44:135-50. [PMID: 32936421 DOI: 10.1007/s13402-020-00557-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
10 Sanchez-Martin C, Menon D, Moroni E, Ferraro M, Masgras I, Elsey J, Arbiser JL, Colombo G, Rasola A. Honokiol Bis-Dichloroacetate Is a Selective Allosteric Inhibitor of the Mitochondrial Chaperone TRAP1. Antioxid Redox Signal 2021;34:505-16. [PMID: 32438819 DOI: 10.1089/ars.2019.7972] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
11 Stoker ML, Newport E, Hulit JC, West AP, Morten KJ. Impact of pharmacological agents on mitochondrial function: a growing opportunity? Biochem Soc Trans 2019;47:1757-72. [PMID: 31696924 DOI: 10.1042/BST20190280] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
12 Ge C, Huang H, Huang F, Yang T, Zhang T, Wu H, Zhou H, Chen Q, Shi Y, Sun Y, Liu L, Wang X, Pearson RB, Cao Y, Kang J, Fu C. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Natl Acad Sci U S A 2019;116:19635-45. [PMID: 31488714 DOI: 10.1073/pnas.1908998116] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
13 Zhu G, Xu P, Guo S, Yi X, Wang H, Yang Y, Liu L, Shi Q, Gao T, Li C. Metastatic Melanoma Cells Rely on Sestrin2 to Acquire Anoikis Resistance via Detoxifying Intracellular ROS. J Invest Dermatol 2020;140:666-675.e2. [PMID: 31476315 DOI: 10.1016/j.jid.2019.07.720] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
14 Fontana F, Raimondi M, Di Domizio A, Moretti RM, Montagnani Marelli M, Limonta P. Unraveling the molecular mechanisms and the potential chemopreventive/therapeutic properties of natural compounds in melanoma. Semin Cancer Biol 2019;59:266-82. [PMID: 31233829 DOI: 10.1016/j.semcancer.2019.06.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
15 Elsey J, Bubley JA, Zhu L, Rao S, Sasaki M, Pollack BP, Yang L, Arbiser JL. Palladium based nanoparticles for the treatment of advanced melanoma. Sci Rep 2019;9:3255. [PMID: 30824801 DOI: 10.1038/s41598-019-40258-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
16 Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma. Cancer Med 2019;8:1186-96. [PMID: 30793515 DOI: 10.1002/cam4.1978] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
17 Preya UH, Jeon C, Lee H, Kang Y, Wang Y, Choi J, Park JH. The Cytotoxic Activity of Honokiol‐Triazole Derivatives in Ovarian Cancer Cells. Bull Korean Chem Soc 2019;40:359-65. [DOI: 10.1002/bkcs.11691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chiu C, Tsai C, Hsieh M, Tsai S, Jan Y, Lin W, Lai D, Wu S, Hsing H, Arbiser JL, Sheu M. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways. Cancer Letters 2019;442:113-25. [DOI: 10.1016/j.canlet.2018.10.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
19 Chio CC, Tai YT, Mohanraj M, Liu SH, Yang ST, Chen RM. Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway. Phytomedicine 2018;49:41-51. [PMID: 30217261 DOI: 10.1016/j.phymed.2018.06.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
20 Fang JY, Huang TH, Hung CF, Huang YL, Aljuffali IA, Liao WC, Lin CF. Derivatization of honokiol by integrated acetylation and methylation for improved cutaneous delivery and anti-inflammatory potency. Eur J Pharm Sci 2018;114:189-98. [PMID: 29241737 DOI: 10.1016/j.ejps.2017.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Akamata K, Wei J, Bhattacharyya M, Cheresh P, Bonner MY, Arbiser JL, Raparia K, Gupta MP, Kamp DW, Varga J. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget 2016;7:69321-36. [PMID: 27732568 DOI: 10.18632/oncotarget.12504] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 15.0] [Reference Citation Analysis]
22 Montagnani V, Benelli M, Apollo A, Pescucci C, Licastro D, Urso C, Gerlini G, Borgognoni L, Luzzatto L, Stecca B. Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget 2016;7:30365-78. [PMID: 27095580 DOI: 10.18632/oncotarget.8758] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
23 Stacpoole PW. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer. J Natl Cancer Inst. 2017;109. [PMID: 29059435 DOI: 10.1093/jnci/djx071] [Cited by in Crossref: 161] [Cited by in F6Publishing: 173] [Article Influence: 26.8] [Reference Citation Analysis]
24 Pearson HE, Iida M, Orbuch RA, McDaniel NK, Nickel KP, Kimple RJ, Arbiser JL, Wheeler DL. Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol Cancer Ther 2018;17:204-14. [PMID: 29054984 DOI: 10.1158/1535-7163.MCT-17-0384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
25 Pal HC, Prasad R, Katiyar SK. Cryptolepine inhibits melanoma cell growth through coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumor suppressor AMPKα1/2-LKB1. Sci Rep 2017;7:1498. [PMID: 28473727 DOI: 10.1038/s41598-017-01659-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
26 Zubair H, Azim S, Ahmad A, Khan MA, Patel GK, Singh S, Singh AP. Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch. Molecules 2017;22:E395. [PMID: 28273819 DOI: 10.3390/molecules22030395] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 11.7] [Reference Citation Analysis]
27 Chamcheu JC, Adhami VM, Esnault S, Sechi M, Siddiqui IA, Satyshur KA, Syed DN, Dodwad SM, Chaves-Rodriquez MI, Longley BJ, Wood GS, Mukhtar H. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice. Antioxid Redox Signal 2017;26:49-69. [PMID: 27393705 DOI: 10.1089/ars.2016.6769] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
28 Lin CJ, Chen TL, Tseng YY, Wu GJ, Hsieh MH, Lin YW, Chen RM. Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway. Toxicol Appl Pharmacol. 2016;304:59-69. [PMID: 27236003 DOI: 10.1016/j.taap.2016.05.018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]